Evaluation of Late Treatment Effects in Long-Term Survivors of Hodgkin's Disease Previously Treated at NIH: A Multi-Institutional Trial
NCT00924131 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 157
Last updated 2017-07-02
Summary
Background:
* Researchers are greatly interested in knowing more about the long-term effects of various treatments for cancers such as Hodgkin's disease, particularly from those who have lived 20 to 30 years after treatment.
* Patients who were treated at the National Institutes of Health (NIH) may have undergone different treatments for which more long-term information is needed.
Objectives:
* To examine the body systems of long-term survivors of Hodgkin's disease to see if there are any long- term consequences of treatment for Hodgkin's disease.
* To learn more about the long-term effects of cancer treatments.
Eligibility:
* Survivors of Hodgkin's disease who were previously treated at the NIH.
* Participants must be at least 18 years of age.
Design:
* Participants will need to sign consent forms to allow researchers to obtain documentation of medical history, including prior treatment for Hodgkin's disease and prior NIH treatment, including protocol number, where applicable:
* Pertinent medical records, pathology reports, and radiographic imaging studies will be reviewed.
* Primary care physician's name, address, and other contact information are also required.
* Evaluations during the assessment period:
* Complete physical examination.
* Laboratory studies of blood, urine, and stool samples.
* Radiologic evaluations, including computerized tomography (CT) and magnetic resonance imaging (MRI) scans for all participants and mammograms for females.
* Cardiac evaluation, vascular studies, and pulmonary studies to measure heart and lung function, and digestive tests to measure stomach and intestinal function.
* Neurocognitive testing to measure brain function.
* Optional skin biopsy.
* Participants will be asked to complete questionnaires assessing current quality of life and daily living skills.
Conditions
- Hodgkin's Disease
- Lymphoma
Sponsors & Collaborators
-
National Cancer Institute (NCI)
lead NIH
Eligibility
- Min Age
- 18 Years
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-04-17
- Completion
- 2010-05-26
Countries
- United States
Study Locations
More Related Trials
-
Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices
NCT02856646 ·Status: COMPLETED
-
High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma
NCT00186394 ·Status: COMPLETED ·Phase: PHASE2
-
Brain Integrity in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation
NCT01820117 ·Status: COMPLETED
-
Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma
NCT02051257 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Observation in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Treated on Clinical Trial CAN-NCIC-LY9
NCT00400907 ·Status: UNKNOWN
-
Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial
NCT00911183 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
NCT00274924 ·Status: COMPLETED ·Phase: PHASE2
-
Risk of Fatigue in Adolescent and Young Adult Hodgkin Lymphoma Patients
NCT01228461 ·Status: COMPLETED
-
Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma
NCT00816959 ·Status: UNKNOWN ·Phase: PHASE3
-
Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
NCT00004112 ·Status: COMPLETED ·Phase: PHASE3
-
Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients
NCT02098512 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma
NCT00193479 ·Status: COMPLETED ·Phase: PHASE2
-
Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET
NCT00188149 ·Status: UNKNOWN ·Phase: PHASE4
-
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma
NCT00003204 ·Status: COMPLETED ·Phase: PHASE3
-
Vaccine Therapy in Treating Patients Who Have Received First-Line Therapy for Hodgkin's Lymphoma
NCT00478062 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Mantle Irradiation for Hodgkin's Disease
NCT00165269 ·Status: COMPLETED ·Phase: PHASE2
-
Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment
NCT00324467 ·Status: UNKNOWN ·Phase: PHASE2
-
Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
NCT00005959 ·Status: UNKNOWN ·Phase: PHASE2
-
Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma
NCT01468311 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00058292 ·Status: COMPLETED ·Phase: PHASE1
-
Cardiac Effects in Long-Term Survivors of Hodgkin's and Non-Hodgkin's Lymphoma
NCT00903890 ·Status: COMPLETED
-
S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma
NCT00006721 ·Status: COMPLETED ·Phase: PHASE3
-
R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma
NCT00809341 ·Status: TERMINATED ·Phase: PHASE2
-
Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma
NCT00088881 ·Status: TERMINATED ·Phase: PHASE2
-
Elderly Hodgkin Lymphoma Patients Treated With Chemoradiotherapy
NCT03535948 ·Status: UNKNOWN